Search

everythinglearnresearchcommunity

for

Search:↓

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

2.5 mg/ml of triamcinolone acetonide is more effective for treating alopecia areata.

The ointment effectively treats neurodermatitis and chronic eczema without causing skin irritation.

The nicotinamide supplement did not reduce symptoms in horses with insect bite hypersensitivity.

Precision neuromodulation may improve schizophrenia symptoms.

Twice-weekly 5 mg betamethasone helps hair regrowth in alopecia areata.

Combining TRA and latanoprost is most effective for treating localized alopecia areata.

These new skin treatments are safer and more effective with minimal side effects.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Selamectin effectively cured the cats' infestation.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

Clascoterone is safe for the heart, even at high doses.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Tideglusib with a bacterial cellulose hydrogel improves wound healing in rats.

Taking oral isotretinoin with creams worked better for treating a type of hair loss than creams alone.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

The new drug delivery system effectively targets lung cancer cells.

Topical calcitriol appears safe and may reduce hair loss during chemotherapy.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Using minoxidil and tofacitinib together can effectively treat severe hair loss.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

The treatment was not recommended due to limited effectiveness and significant side effects.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.